Compare RYAAY & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAAY | IQV |
|---|---|---|
| Founded | 1985 | 1982 |
| Country | Ireland | United States |
| Employees | 25952 | 93000 |
| Industry | Air Freight/Delivery Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7B | 28.6B |
| IPO Year | N/A | 2013 |
| Metric | RYAAY | IQV |
|---|---|---|
| Price | $55.99 | $181.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $78.00 | ★ $227.13 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $11.99 | $6.77 |
| Revenue Next Year | $6.32 | $5.89 |
| P/E Ratio | ★ $12.60 | $115.68 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $53.14 | $153.23 |
| 52 Week High | $74.24 | $247.05 |
| Indicator | RYAAY | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 54.12 |
| Support Level | $55.43 | $176.99 |
| Resistance Level | $61.70 | $182.20 |
| Average True Range (ATR) | 1.43 | 7.00 |
| MACD | -0.22 | 0.73 |
| Stochastic Oscillator | 2.52 | 65.45 |
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 flights daily across 240-plus destinations in 40 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.